Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 14/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8824386 | 0.86 | TACR1 (0.67) | TACR1OPRM1SLC6A4KCNH2 | |
| Hydrochloric Acid SCHEMBL8824373 | 0.84 | TACR1 (0.66) | TACR1OPRM1SLC6A4KCNH2TSHR | |
| SCHEMBL9669305 | 0.84 | TACR1 (0.55) | TACR1OPRM1SLC6A4KCNH2TSHR | |
| SCHEMBL8824356 | 0.82 | TACR1 (1.00) | TACR1SLC6A4KCNH2 | |
| Hydrochloric Acid SCHEMBL8824383 | 0.81 | TACR1 (0.98) | TACR1SLC6A4KCNH2 | |
| SCHEMBL12492922 | 0.79 | TACR1 (0.46) | TACR1OPRM1TSHRMEN1KMT2A | |
| SCHEMBL6381424 | 0.78 | SLC6A4 (0.69) | TACR1OPRM1SLC6A4 | |
| SCHEMBL8824368 | 0.78 | TACR1 (0.52) | TACR1TSHRMEN1KMT2A | |
| SCHEMBL5736780 | 0.77 | L3MBTL1 (0.46) | TACR1OPRM1SLC6A4TSHRHTT | |
| Hydrochloric Acid SCHEMBL8824364 | 0.77 | HTR2A (0.51) | TACR1MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| EP-1501467-A4 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2009-08-19 | — | — | EP | disclosed |
| EP-1501467-A2 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | Bristol-Myers Squibb Company (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003088908-A2 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-10-30 | — | — | WO | disclosed |
| EP-1126849-A4 | HETEROCYCLIC POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2003-06-04 | — | — | EP | disclosed |
| EP-1126849-A1 | HETEROCYCLIC POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000025786-A1 | HETEROCYCLIC POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNH2, KCNQ5 | TACR1 3354/4885OPRM1 2850/4885SLC6A4 2532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.